BioLineRx to study BL-8040 in Phase Ib/II trial for pancreatic cancer treatment
Israeli company BioLineRx has started a Phase Ib/II clinical trial of its BL-8040 in combination with Roche Group subsidiary Genentech's atezolizumab (Tecentriq) to treat pancreatic cancer.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Israel Health | Pancreas | Pancreatic Cancer | Pharmaceuticals | Study